The European Union’s drug regulator says it has launched an accelerated review process for an experimental coronavirus vaccine booster made by the Spanish company Hyper.
The European Medicines Agency said in a statement that its assessment was based on preliminary data from laboratory research and adult research that compared the Hyper Booster shot with a Pfizer-Biotech vaccine. It states that preliminary results indicate that the immune response acquired with Hipra may be “effective” against Covid-19, which contains a large infectious omikron form.
Hipra is a protein-based vaccine and has been developed using technology similar to the Novavax COVID-19 vaccine, which was approved by the EMA and other agencies in December. It contains two versions of the coronavirus spike protein that were developed in a lab, which are intended for an immune response when a person is vaccinated.
Hipra is intended to be a booster shot for people who have been fully vaccinated with a messenger RNA vaccine or vector-based vaccine, such as AstraZeneca and Johnson & Johnson.
Scientists believe that using a variety of vaccines can boost the body’s immune system, and many countries have adopted a “mixed-and-match” strategy to vaccinate against COVID-19.
Hipra has reportedly sold millions of its vaccines in Vietnam and estimates that it could produce about 600 million doses this year.
Follow AP coverage of the epidemic at https://apnews.com/hub/coronavirus-pandemic